Updated Guidelines for Diagnosing and Managing Heart Failure in Pregnancy and Postpartum
New guidelines from the Society for Maternal-Fetal Medicine highlight the importance of early diagnosis and multidisciplinary management of heart failure during pregnancy and postpartum to improve maternal and neonatal outcomes.
The Society for Maternal-Fetal Medicine (SMFM) has released new clinical guidance emphasizing the importance of early diagnosis, comprehensive counseling, and specialized management of heart failure during pregnancy and the postpartum period. Heart disease remains a leading cause of maternal mortality in the United States, particularly affecting non-Hispanic Black populations, with heart failure significantly contributing to maternal complications.
Effective management begins with preconception counseling, where women with known heart failure are assessed for risks and provided tailored advice. For those with severe pulmonary arterial hypertension or notably low ejection fractions (less than 30%), pregnancy continuation may not be advisable, and specialized centers equipped with multidisciplinary Pregnancy Heart Teams are recommended. Women with a history of peripartum cardiomyopathy should receive individualized counseling regarding the risks of recurrence.
Medications play a critical role in treatment; certain drugs like SGLT2 inhibitors, spironolactone, ACE inhibitors, ARBs, and ARNIs should be discontinued before or during pregnancy due to potential fetal risks, with alternatives like hydralazine considered. Beta-blockers such as metoprolol, carvedilol, and bisoprolol are generally safe to continue. Postpartum care necessitates close cardiovascular monitoring because risks of severe complications persist after delivery. Breastfeeding considerations include reviewing medication safety for the infant.
Delivery planning involves assembling a multidisciplinary team to ensure optimal care, with vaginal delivery prioritized unless obstetric indications necessitate cesarean section. Most women with uncomplicated heart failure should aim for delivery at term.
The guidelines underscore the need for ongoing postpartum surveillance to mitigate maternal morbidity and mortality, emphasizing that early detection and management can significantly improve both maternal and neonatal health outcomes.
For more details, consult the SMFM's Series #73 publication in Pregnancy.
Source: https://medicalxpress.com/news/2025-10-guidance-heart-failure-pregnancy-postpartum.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Electrical Stimulation of Facial Muscles Alters Emotional Perception and Brain Responses
New research reveals that stimulating facial muscles influences how people perceive emotions and alters brain responses, offering insights into social cognition and potential clinical applications.
FDA Approves Inluriyo for Advanced Breast Cancer Treatment
The FDA has approved Eli Lilly's Inluriyo, an oral treatment for ESR1-mutated advanced breast cancer, offering new hope for patients with treatment-resistant disease after successful clinical trial results.
Star-Shaped Brain Cells Offer New Hope for Personalized Bipolar Disorder Treatment
Research uncovers metabolic differences in astrocytes based on lithium response, paving the way for personalized bipolar disorder treatments.
Enhancing Cancer Diagnosis Speed Through Connected Health Data
Advances in connected health data are paving the way for earlier and more reliable cancer diagnoses, transforming patient care and outcomes through comprehensive data analysis and system-wide improvements.